| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910512168903321 |
|
|
Titolo |
Flow chemistry in drug discovery / / Jesus Alcazar, Antonio de la Hoz and Angel Díaz-Ortiz, editors |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham, Switzerland : , : Springer Nature Switzerland AG, , [2021] |
|
©2021 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (479 pages) : illustrations |
|
|
|
|
|
|
Collana |
|
Topics in Medicinal Chemistry ; ; Volume 38 |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Drug development |
Flow chemistry |
Pharmaceutical chemistry |
Technology, Pharmaceutical |
Drug Discovery |
Chemistry - instrumentation |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Sommario/riassunto |
|
This book reviews the challenges and opportunities posed by flow chemistry in drug discovery, and offers a handy reference tool for medicinal chemists interested in the synthesis of biologically active compounds. Prepared by expert contributors, the respective chapters cover not only fundamental methodologies and reactions, such as the application of catalysis, especially biocatalysis and organocatalysis; and non-conventional activation techniques, from photochemistry to electrochemistry; but also the development of new process windows, processes and reactions in drug synthesis. Particular attention is given to automatization and library synthesis, which are of great importance in the pharmaceutical industry. Readers will also find coverage on selected topics of general interest, such as how flow chemistry is contributing to drug discovery R&D in developing countries, and the green character of this enabling technology, for example in the production of raw materials for the pharmaceutical industry from waste. Given its scope, the book appeals to medicinal chemistry |
|
|
|
|
|
|
|
|
|
|
researchers working in academia and industry alike, as well as professionals involved in scale-up and drug development. |
|
|
|
|
|
| |